| Psoriasis vulgaris
Siliq vs Stelara
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Siliq vs Stelara with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStelara has a higher rate of injection site reactions vs Siliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stelara but not Siliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Siliq
Stelara
At A Glance
Subcutaneous
Every 2 weeks
IL-17RA antagonist
SC injection
Every 8-12 weeks
IL-12/23 antagonist
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
Dosing
Psoriasis vulgaris 210 mg subcutaneously at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.
Psoriasis vulgaris Adults <=100 kg: 45 mg SC at weeks 0 and 4, then every 12 weeks; adults >100 kg: 90 mg SC at weeks 0 and 4, then every 12 weeks; pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for 60-100 kg, 90 mg for >100 kg) SC at weeks 0 and 4, then every 12 weeks.
Arthritis, Psoriatic Adults: 45 mg SC at weeks 0 and 4, then every 12 weeks (90 mg for >100 kg with co-existent moderate-to-severe plaque psoriasis); pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for >=60 kg, 90 mg for >100 kg with co-existent plaque psoriasis) SC at weeks 0 and 4, then every 12 weeks.
Crohn Disease, Ulcerative Colitis Adults: single IV induction dose (260 mg for <=55 kg, 390 mg for >55-85 kg, 520 mg for >85 kg), followed by 90 mg SC at week 8, then every 8 weeks.
Contraindications
- Crohn's disease
- Clinically significant hypersensitivity to brodalumab or to any of the excipients
- Clinically significant hypersensitivity to ustekinumab or any excipient of STELARA
Adverse Reactions
Most common (>=1%) Arthralgia (4.7%), headache (4.3%), fatigue (2.6%), diarrhea (2.2%), oropharyngeal pain (2.1%), nausea (1.9%), myalgia (1.7%), injection site reactions (1.5%), influenza (1.3%), neutropenia (1.0%), tinea infections (1.0%).
Serious Suicidal ideation and behavior (0.37 per 100 subject-years), infections including fungal infections, neutropenia grade >=3.
Postmarketing Hypersensitivity reactions, anaphylaxis including anaphylactic shock, pruritus, rashes, eczema, urticaria, dermatitis, eczematous eruptions (atopic dermatitis-like eruptions).
Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, headache, fatigue, back pain, dizziness, pharyngolaryngeal pain, pruritus, injection site erythema, myalgia, depression
Serious Infections, malignancies, serious hypersensitivity reactions, posterior reversible encephalopathy syndrome (PRES), noninfectious pneumonia
Postmarketing Hypersensitivity reactions (anaphylaxis, angioedema, dyspnea, rash, urticaria), lower respiratory tract infection, PRES, interstitial pneumonia, eosinophilic pneumonia, cryptogenic organizing pneumonia, pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis
Pharmacology
Brodalumab is a human monoclonal IgG2 antibody that selectively binds to IL-17RA and inhibits its interactions with IL-17 family cytokines (IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, IL-25), thereby blocking IL-17 cytokine-induced pro-inflammatory responses.
Ustekinumab is a human IgG1k monoclonal antibody that binds the p40 protein subunit shared by IL-12 and IL-23, blocking their interaction with the IL-12Rb1 receptor chain and thereby suppressing downstream inflammatory signaling involved in natural killer cell activation and CD4+ T-cell differentiation and activation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Siliq
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Stelara
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Siliq
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Stelara
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Siliq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Stelara
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$50/momo
Siliq Solutions Instant Savings Program - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Stelara withMe Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
StelaraView full Stelara profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.